Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Alain Vergnenègre1, Joshua A Ray2, Christos Chouaid3, Francesco Grossi4, Helge G Bischoff5, David F Heigener6, Stefan Walzer21Department of Pneumology, Hôpital du Cluzeau, Limoges, France; 2Global Health Economics and Strategic Pricing, F Hoffmann-La Roche Ltd, Basel, Sw...

Full description

Bibliographic Details
Main Authors: Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S
Format: Article
Language:English
Published: Dove Medical Press 2012-01-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/cross-market-cost-effectiveness-analysis-of-erlotinib-as-first-line-ma-a9142

Internet

http://www.dovepress.com/cross-market-cost-effectiveness-analysis-of-erlotinib-as-first-line-ma-a9142

Similar Items